X4 Pharmaceuticals Inc
XFOR1.580USD
-0.020-1.25%
收盘 08/04, 16:00（美东）报价延迟15分钟
304.87K总市值
0.02市盈率 TTM
关于 X4 Pharmaceuticals Inc 公司
X4 Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现和开发用于治疗罕见疾病和治疗选择有限的疾病的新型疗法，重点是治疗由免疫系统功能障碍引起的疾病。其主要临床候选药物是 mavorixafor，一种趋化因子受体 CXCR4 的小分子选择性拮抗剂，正在开发为口服、每日一次的疗法。该公司已经开发了一系列趋化因子受体 CXC 受体 4 型 (CXCR4) 的小分子口服拮抗剂。该公司有两种临床前候选药物：X4P-003，一种第二代 CXCR4 拮抗剂，旨在具有比 mavorixafor 更强的特性，可能为 CXCR4 依赖性疾病和原发性免疫缺陷提供机会，以及 X4P-002，一种具有分布特征和已证实能够穿过血脑屏障的 CXCR4 拮抗剂。
公司简介
公司代码XFOR
公司名称X4 Pharmaceuticals Inc
上市日期Nov 16, 2017
CEODr. Paula Ragan, Ph.D.
员工数量143
证券类型Ordinary Share
年结日Nov 16
公司地址61 North Beacon Street
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02134
电话18575298300
网址https://www.x4pharma.com/
公司代码XFOR
上市日期Nov 16, 2017
CEODr. Paula Ragan, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
5.56K
+36.98%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
5.34K
+23.97%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
4.72K
+46.55%
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Mr. Adam S. Mostafa
Mr. Adam S. Mostafa
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
--
--
Dr. Christophe Arbetengels, Ph.D.
Dr. Christophe Arbetengels, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
5.56K
+36.98%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
5.34K
+23.97%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
4.72K
+46.55%
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月23日 周三
更新时间: 7月23日 周三
持股股东
股东类型
持股股东
持股股东
占比
Bain Capital Life Sciences Investors, LLC
9.52%
New Enterprise Associates (NEA)
8.43%
BlackRock Institutional Trust Company, N.A.
5.97%
The Vanguard Group, Inc.
4.54%
Acorn Capital Advisors, LLC
4.11%
Other
67.43%
持股股东
持股股东
占比
Bain Capital Life Sciences Investors, LLC
9.52%
New Enterprise Associates (NEA)
8.43%
BlackRock Institutional Trust Company, N.A.
5.97%
The Vanguard Group, Inc.
4.54%
Acorn Capital Advisors, LLC
4.11%
Other
67.43%
股东类型
持股股东
占比
Investment Advisor
30.62%
Venture Capital
8.46%
Hedge Fund
7.05%
Investment Advisor/Hedge Fund
5.75%
Private Equity
4.96%
Individual Investor
2.82%
Research Firm
0.91%
Bank and Trust
0.09%
Pension Fund
0.04%
Other
39.30%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
221
3.60M
60.71%
-1.69M
2025Q1
225
3.45M
58.17%
-2.00M
2024Q4
216
103.66M
60.78%
-53.08M
2024Q3
212
110.90M
65.83%
-43.36M
2024Q2
209
114.19M
68.28%
-40.11M
2024Q1
203
115.38M
69.15%
-30.64M
2023Q4
192
109.42M
65.98%
-32.86M
2023Q3
189
132.64M
89.63%
+450.20K
2023Q2
191
133.25M
115.52%
+52.30M
2023Q1
171
81.27M
73.10%
+5.35M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Bain Capital Life Sciences Investors, LLC
563.86K
9.52%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
499.56K
8.43%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
353.91K
5.97%
+11.94K
+3.49%
Mar 31, 2025
The Vanguard Group, Inc.
268.92K
4.54%
-4.45K
-1.63%
Mar 31, 2025
Acorn Capital Advisors, LLC
243.69K
4.11%
--
--
Mar 31, 2025
Kingdon Capital Management, L.L.C.
233.33K
3.94%
+68.77K
+41.79%
Mar 31, 2025
OrbiMed Advisors, LLC
225.88K
3.81%
-11.90K
-5.00%
Mar 31, 2025
UBS Financial Services, Inc.
167.91K
2.83%
+137.14K
+445.70%
Mar 31, 2025
Geode Capital Management, L.L.C.
120.66K
2.04%
+4.08K
+3.50%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Simplify Propel Opportunities ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 2000 Growth ETF
0%
Vanguard US Momentum Factor ETF
0%
查看更多
ProShares UltraPro Russell2000
占比0%
iShares Russell 2000 Value ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Proshares Ultra Russell 2000
占比0%
Simplify Propel Opportunities ETF
占比0%
Global X Russell 2000 ETF
占比0%
iShares Russell 2000 ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
Vanguard US Momentum Factor ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
